Spalcarb 50/150/450 50 mg, 150 mg, 450 mg CONCENTRATE FOR SOLUTION FOR INFUSION
PDF Leaflet Revision Date: 13 December 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced ovarian carcinoma and limited evidence for small cell lung carcinoma.
Dosage (summary)
400 mg/mu00b2 IV as a single dose; adjust for renal impairment and elderly.
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Aluminium-containing devices
- Oral anticoagulants
- Ciclosporin
Contraindications
- Hypersensitivity to carboplatin
- Severe renal impairment
- Severe myelosuppression
- Pregnancy
Common side effects
- Myelosuppression
- Nausea
- Vomiting
- Ototoxicity
- Visual disturbances
Counselling Points
- Monitor blood counts regularly
- Avoid pregnancy during treatment
- Use antiemetics for nausea
Serious warnings
- Hypersensitivity reactions
- Myelosuppression
- Haemolytic-uremic syndrome
- Neurologic toxicity
Important Disclaimer
The Spalcarb 50/150/450 50 mg, 150 mg, 450 mg CONCENTRATE FOR SOLUTION FOR INFUSION professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
